Marimed Inc. Q4 2025: Revenue Grows 3.5%, Loss Per Share Narrows to –$0.01
Marimed Inc. reports Q4 2025 results: slight revenue rise to $40.4 M, but continuing losses –$0.01 EPS; investors watch for conversion to profitability.
2 minutes to read
MariMed Inc
MariMed Inc. Expands into Pennsylvania with TILT Holdings Partnership
MariMed Inc. has expanded into the Pennsylvania market through a strategic partnership with TILT Holdings, leveraging its expertise in medical cannabis cultivation and production to tap into a new market.
2 minutes to read
MariMed Inc. Reports Q1 2025 Loss Amid Strategic Efforts to Expand in Cannabis Market
MariMed Inc. reported a loss for Q1 2025, falling short of revenue estimates, but CEO Jon Levine emphasized the company’s commitment to expanding its market presence and product offerings in the cannabis industry.
2 minutes to read